Castrate-resistant prostate cancer: therapeutic strategies

Abstract

Importance of the field: Castrate-resistant prostate cancer continues to be inadequately addressed by currently available therapies.

Areas covered in this review: This review will discuss recent developments, including new chemotherapies and chemotherapy regimens, antiangiogenic therapy, immunotherapy, and other new agents, such as endothelin-A receptor antagonists and clusterin inhibitors.

What the reader will gain: The reader will gain an understanding of the therapies in development for castration-resistant disease.

Take home message: Therapies focused on multiple different targets are currently being studied for castrate-resistant prostate cancer.

Keywords::

• abiraterone
• angiogenesis
• bevacizumab
• castrate-resistant
• chemotherapy
• endothelin
• immunotherapy
• ixabepilone
• Phase III
• prostate cancer

Notes

This box summarizes key points contained in the article.